Evaluation of the effect of selective serotonin-reuptake inhibitors on lymphocyte subsets in patients with a major depressive disorder

European Neuropsychopharmacology

Volumn 20, Issue 2, 2010, Pages 88-95

  Hernandez, Maria Eugenia ^a,b   Martinez Fong, Daniel ^c   Perez Tapia, Mayra ^d   Estrada Garcia, Iris ^d   Estrada Parra, Sergio ^d   Pavón, Lenin ^a  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b UAM   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

5 HT; B lymphocyte; CD4+ cells; CD8+ cells; Major Depressive Disorder; NK cells

Indexed keywords

ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; BECK DEPRESSION INVENTORY; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HAMILTON SCALE; HUMAN; LONG TERM CARE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR DEPRESSION; MALE; NATURAL KILLER T CELL; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION;

ADULT; B-LYMPHOCYTES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; SEROTONIN UPTAKE INHIBITORS; T-LYMPHOCYTES;

EID: 73249134158     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.11.005     Document Type: Article

References (52)

1. Abdouh M., Albert P.R., Drobetsky E., Filep J.G., and Kouassi E. 5-HT1A-mediated promotion of mitogen-activated T and B cell survival and proliferation is associated with increased translocation of NF-kappaB to the nucleus. Brain Behav. Immun. 18 (2004) 24-34
2. Ader R., Felten D.L., and Cohen N. Psychoneuroimmunology (2001), Academic Press, San Diego California, USA
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (1994), American Psychiatric Association, Washington, DC
4. Andreoli A.V., Keller S.E., Rabaeus M., Marin P., Bartlett J.A., and Taban C. Depression and immunity: age, severity, and clinical course. Brain Behav. Immun. 7 (1993) 279-292
5. Barkan T., Gurwitz D., Levy G., Weizman A., and Rehavi M. Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. Eur. Neuropsychopharmacol. 14 (2004) 237-243
6. Beck A.T., Steer R.A., Beck J.S., and Newman C.F. Hopelessness, depression, suicidal ideation, and clinical diagnosis of depression. Suicide Life Threat. Behav. 23 (1993) 139-145
7. Blardi P., De Lalla A., Leo A., Auteri A., Iapichino S., Di M.A., Dell'Erba A., and Castrogiovanni P. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J. Clin. Psychopharmacol. 22 (2002) 131-136
8. Blardi P., de L.A., Urso R., Auteri A., Dell'Erba A., Bossini L., and Castrogiovanni P. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. J. Clin. Psychopharmacol. 25 (2005) 262-266
9. Castrogiovanni P., Blardi P., De Lalla A., Dell'Erba A., and Auteri A. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?. Psychopharmacol. Bull. 37 (2003) 102-108
10. Druker J., Liberman A.C., Acuna M., Giacomini D., Refojo D., Silberstein S., Pereda M.P., Stalla G.K., Holsboer F., and Arzt E. Molecular understanding of cytokine-steroid hormone dialogue: implications for human diseases. Ann. N. Y. Acad. Sci. 1088 (2006) 297-306
11. Elenkov I.J. Glucocorticoids and the Th1/Th2 balance. Ann. N. Y. Acad. Sci. 1024 (2004) 138-146
12. Fazzino F., Montes C., Urbina M., Carreira I., and Lima L. Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation. J. Neuroimmunol. 196 (2008) 173-180
13. Frank M.G., Hendricks S.E., Burke W.J., and Johnson D.R. Clinical response augments NK cell activity independent of treatment modality: a randomized double-blind placebo controlled antidepressant trial. Psychol. Med. 34 (2004) 491-498
14. Frank M.G., Johnson D.R., Hendricks S.E., and Frank J.L. Monocyte 5-HT1A receptors mediate pindobind suppression of natural killer cell activity: modulation by catalase. Int. Immunopharmacol. 1 (2001) 247-253
15. Frick L.R., Rapanelli M., Cremaschi G.A., and Genaro A.M. Fluoxetine directly counteracts the adverse effects of chronic stress on T cell immunity by compensatory and specific mechanisms. Brain Behav. Immun. 23 (2009) 36-40
16. Gillespie C.F., and Nemeroff C.B. Hypercortisolemia and depression. Psychosom. Med. 67 Suppl 1 (2005) S26-S28
17. Gladkevich A., Kauffman H.F., and Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 559-576
18. Green A.R. Neuropharmacology of 5-hydroxytryptamine. Br. J. Pharmacol. 147 Suppl 1 (2006) S145-S152
19. Griffiths J., Ravindran A.V., Merali Z., and Anisman H. Neuroendocrine measures and lymphocyte subsets in depressive illness: influence of a clinical interview concerning life experiences. Psychoneuroendocrinology 22 (1997) 225-236
20. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., and Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res. 33 (1999) 407-418
21. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
22. Heinze,G.. M.I.N.I. 5.0.0. Mini International Neuropsychiatric Interview. [Spanish South and Central America version/DSM-IV]. 2000. Sheehan DV and Lecubrier Y.
23. Hellstrand K., and Hermodsson S. Serotonergic 5-HT1A receptors regulate a cell contact-mediated interaction between natural killer cells and monocytes. Scand. J. Immunol. 37 (1993) 7-18
24. Hernandez M.E., Mendieta D., Martinez-Fong D., Loria F., Moreno J., Estrada I., Bojalil R., and Pavon L. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur. Neuropsychopharmacol. 18 (2008) 917-924
25. Hsueh C.M., Chen S.F., Lin R.J., and Chao H.J. Cholinergic and serotonergic activities are required in triggering conditioned NK cell response. J. Neuroimmunol. 123 (2002) 102-111
26. Iken K., Chheng S., Fargin A., Goulet A.C., and Kouassi E. Serotonin upregulates mitogen-stimulated B lymphocyte proliferation through 5-HT1A receptors. Cell. Immunol. 163 (1995) 1-9
27. Jozuka H., Jozuka E., Takeuchi S., and Nishikaze O. Comparison of immunological and endocrinological markers associated with major depression. J. Int. Med. Res. 31 (2003) 36-41
28. Karege F., Widmer J., Bovier P., and Gaillard J.M. Platelet serotonin and plasma tryptophan in depressed patients: effect of drug treatment and clinical outcome. Neuropsychopharmacology 10 (1994) 207-214
29. Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr. Opin. Pharmacol. 8 (2008) 460-471
30. Lima L., and Urbina M. Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cell. Mol. Neurobiol. 22 (2002) 797-804
31. Maes M., Lin A., Bonaccorso S., van H.F., Van G.A., Delmeire L., Biondi M., Bosmans E., Kenis G., and Scharpe S. Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr. Scand. 98 (1998) 328-335
32. Maes M., Stevens W., DeClerck L., Bridts C., Peeters D., Schotte C., and Cosyns P. Immune disorders in depression: higher T helper/T suppressor-cytotoxic cell ratio. Acta Psychiatr. Scand. 86 (1992) 423-431
33. Maletic V., Robinson M., Oakes T., Iyengar S., Ball S.G., and Russell J. Neurobiology of depression: an integrated view of key findings. Int. J. Clin. Pract. 61 (2007) 2030-2040
34. Mason B.L., and Pariante C.M. The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News Perspect. 19 (2006) 603-608
35. Mata S., Urbina M., Manzano E., Ortiz T., and Lima L. Noradrenaline transporter and its turnover rate are decreased in blood lymphocytes of patients with major depression. J. Neuroimmunol. 170 (2005) 134-140
36. Mossner R., and Lesch K.P. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav. Immun. 12 (1998) 249-271
37. Nemeroff C.B., and Owens M.J. Treatment of mood disorders. Nat. Neurosci. 5 (2002) 1068-1070
38. Nichols J.H., Charlson J.R., and Lawson G.M. Automated HPLC assay of fluoxetine and norfluoxetine in serum. Clin. Chem. 40 (1994) 1312-1316
39. Nikisch G., Mathe A.A., Czernik A., Thiele J., Bohner J., Eap C.B., Agren H., and Baumann P. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl) 181 (2005) 751-760
40. Ortiz-Dominguez A., Hernandez M.E., Berlanga C., Gutierrez-Mora D., Moreno J., Heinze G., and Pavon L. Immune variations in bipolar disorder: phasic differences. Bipolar. Disord. 9 (2007) 596-602
41. Pariante C.M., and Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49 (2001) 391-404
42. Pavon L., Sandoval-Lopez G., Eugenia H.M., Loria F., Estrada I., Perez M., Moreno J., Avila U., Leff P., Anton B., and Heinze G. Th2 cytokine response in major depressive disorder patients before treatment. J. Neuroimmunol. 172 (2006) 156-165
43. Pellegrino T.C., and Bayer B.M. Role of central 5-HT(2) receptors in fluoxetine-induced decreases in T lymphocyte activity. Brain Behav. Immun. 16 (2002) 87-103
44. Pena S., Baccichet E., Urbina M., Carreira I., and Lima L. Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients. Int. Immunopharmacol. 5 (2005) 1069-1076
45. Ravindran A.V., Griffiths J., Merali Z., and Anisman H. Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment. Psychosom. Med. 57 (1995) 555-563
46. Ravindran A.V., Griffiths J., Merali Z., and Anisman H. Circulating lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls. J. Affect. Disord. 52 (1999) 1-10
47. Rothermundt M., Arolt V., Fenker J., Gutbrodt H., Peters M., and Kirchner H. Different immune patterns in melancholic and non-melancholic major depression. Eur. Arch. Psychiatry Clin. Neurosci. 251 (2001) 90-97
48. Schleifer S.J., Keller S.E., and Bartlett J.A. Depression and immunity: clinical factors and therapeutic course. Psychiatry Res. 85 (1999) 63-69
49. Stokes P.E., Maas J.W., Davis J.M., Koslow S.H., Casper R.C., and Stoll P.M. Biogenic amine and metabolite levels in depressed patients with high versus normal hypothalamic-pituitary-adrenocortical activity. Am. J. Psychiatry 144 (1987) 868-872
50. Teicher M.H., Andersen S.L., Polcari A., Anderson C.M., Navalta C.P., and Kim D.M. The neurobiological consequences of early stress and childhood maltreatment. Neurosci. Biobehav. Rev. 27 (2003) 33-44
51. World Health Organization. Adherence to long term therapies: evidence for action. Switzerland (2003)
52. Zorrilla E.P., Luborsky L., McKay J.R., Rosenthal R., Houldin A., Tax A., McCorkle R., Seligman D.A., and Schmidt K. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 15 (2001) 199-226